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We select the letters for these pages from the rapid 
responses posted on bmj.com favouring those received 
within five days of publication of the article to which they 
refer. Letters are thus an early selection of rapid responses 
on a particular topic. Readers should consult the website 
for the full list of responses and any authors’ replies, which 
usually arrive after our selection.
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Continuous deep sedation
Please, don’t forget ethical 
responsibilities
A caveat to the assumption that terminal or 
palliative sedation can be accepted as the norm 
by healthcare professionals is that patients and 
their relatives should be contacted and their 
wishes, where possible, properly obtained.1 This 
is not as straightforward as it sounds.
My own, previously well and robust, 92 year 
old father was admitted as a medical emergency 
with rectal haemorrhage. He had moved to live 
in a rest home three weeks earlier because of 
deteriorating health of uncertain cause, having 
spent all of his life living independently and in 
robust health (and fully lucid). On admission 
his haemoglobin was about 60 g/l, and 
initial resuscitation, blood transfusion, was 
successful. However, an urgent abdominal 
computed tomography scan showed a locally 
invading colonic carcinoma at the splenic 
flexure—with little chance he might survive 
surgery or, at least, long after it, and terminal 
sedation was decided on. Neither he (I later 
discovered) nor any of his close family was 
consulted before such a decision, and treatment 
was implemented immediately. My brother 
and I, his only first degree relatives, were both 
overseas and returned to the United Kingdom 
to be with him. My brother arrived the next day 
only to discover he was deeply unconscious. 
He lived three days in total until two hours after 
I arrived at the hospital. At this point he was 
warm, well perfused with a good cardiovascular 
output—so hardly haemorrhaging to death. 
After a 36 hour shuttle across the world having 
learnt he was sitting up, chatting, and vowing to 
recover (admittedly pre-diagnosis), to find him 
close to death was a little distressing. No drip, 
heavy sedation increasingly infused. Protocol 
successful; patient died quietly with his family. 
No goodbyes. 
I was quite upset to learn that my father 
had no knowledge of his fate and I therefore 
investigated his care in more detail. I was then 
able to confirm that he had never consented to 
terminal sedation, and, although he knew his 
condition was not curable (not documented), 
he was certainly not aware that he would shortly 
die as was evidenced by the statements he 
made to friends. And as his sons were flying to 
his side surely he would have wanted to see 
and talk to us before he died. Isn’t that obvious? 
Obviously not. Of course, once the facts were 
established, I received a profound and honest 
apology from the hospital, but I only received 
this after they had initially incorrectly made 
a statement in writing that he had received 
terminal sedation because he was “distressed” 
and “in pain.” Not only was this refuted by 
visitors but the notes made no reference to pain 
or distress, whatsoever. By all accounts he was 
actually feeling quite well. So was this terminal 
euthanasia in another guise—or was this worse?
Terminal sedation is not simply to expedite 
demise in order to free up costly specialist 
facilities. Far better to discharge such patients to 
hospice care where caring for the terminally ill is 
done with greater expertise and sensitivity. I only 
discovered these facts because I am a doctor 
and had the “brass neck” to ask. I am quite 
concerned what could well be going on out there 
in the name of caring and terminal sedation.
Philip J Harrison general practitioner, Upper hutt,  
Wellington, New Zealand philipharrison@xtra.co.nz
Competing interests: PJh’s father was subjected to terminal 
sedation courtesy of medical and nursing team.
Murray SA, Boyd K, Byock I. Continuous deep sedation in 1 
patients nearing death. BMJ 2008;336:781-2. (12 April.) 
Good care at the end of life,  
not hastening death
Treloar misunderstands the fundamental 
premise of the Liverpool care pathway (LCP).1 
A patient is put on the pathway only once it is 
recognised they are dying imminently, within 
hours to a few days.2 The evidence does not 
support that artificial hydration or nutrition has a 
role to ease symptoms and suffering and may, in 
fact, add to it.3 
Deep sedation is not recommended as part 
of the Liverpool care pathway and is not usual 
practice in UK palliative care teaching. Sedation 
can be a feature of symptom management but 
is not the prime aim. Morphine will be used to 
treat pain or breathlessness, glycopyrronium 
to treat bubbly secretions, haloperidol to treat 
nausea or agitation and delirium, midazolam 
to treat distress, etc. Most patients do not need 
large doses of these medications to achieve 
the necessary symptom control. In a study from 
St Christopher’s Hospice, dose increases in 
sedative medication at the end of life were not 
associated with a shortened survival.4
The key assessment is the identification of 
dying. The focus of care is then clarified, and the 
pathway provides a structured format to achieve 
this. It is unhelpful to raise concerns about 
hastening death by deep sedation or denying 
hydration and only fuels misunderstanding 
and fear. The introduction of the pathway must 
be supported by a comprehensive teaching 
programme, and the structure of the tool 
supports regular evaluation and audit.
The pathway is not a fait accompli to dying and 
occasionally patients get better and come off the 
pathway. In the acute general hospital I work in, 
where we have supported over 300 patients on 
the LCP, this has occurred on 14 occasions.
This is an essential time to be effective 
clinicians. Poor experiences of dying will 
resonate in relatives’ memories. The Liverpool 
care pathway supports clinicians to get it right.
lulu Kreeger consultant palliative medicine 
kingston hospital Nhs trust and Princess alice hospice, 
Esher kt10 8Na luluk@globalnet.co.uk
Competing interests: None declared.
Treloar AJ. Dutch research reflects problems with the 1 
Liverpool care pathway. BMJ 2008;336:905. (26 April.) 
Marie Curie Palliative Care Institute. Liverpool care 2 
pathway for the dying patient (LCP), 2008. www.mcpcil.
org.uk/liverpool_care_pathway 
Campbell C, R Partridge. 3 Artificial nutrition and 
hydration. Guidance in end of life care for adults. 
National Council for Palliative Care, 2007. 
Sykes N, Thorns A. The use of opioids and sedatives at 4 
the end of life. Lancet Oncol 2003;4:312-8. 
rapid sCreening for Mrsa
Preventing infections from 
cannulas reduces MRSA
We have shown through bacteraemia 
surveillance (June 2003-December 2006) that 
19 of 118 episodes (16.1%) of bacteraemia 
due to hospital acquired MRSA on medical 
and surgical wards were secondary to infected 
insertion sites of peripheral cannulas. In June 
2007, King George Hospital, Barking, Havering 
1086    BMJ | 17 MAY 2008 | VoluMe 336 
Saving Lives: reducing infection, delivering clean 1 
and safe care. Peripheral intravenous cannula care 
bundle. www.clean-safe-care.nhs.uk
Jeyaratnam D, Whitty CJM, Phillips K, Liu D, Orezzi 2 
C, Ajoku U,et al. Impact of rapid screening tests on 
acquisition of meticillin resistant Staphylococcus 
aureus: cluster randomised crossover trial. BMJ 
2008;336:927-30. (26 April.) 
 
Blunt aBdoMinal trauMa
Note of caution on diagnostic 
peritoneal lavage
Jansen et al highlight the potential difficulty 
of diagnosing intraperitoneal bleeding and 
hollow viscus injuries in patients with blunt 
abdominal trauma.1 Despite an increasing 
use of point of care focused assessment with 
sonography for trauma (FAST), diagnostic 
peritoneal lavage continues to be taught on 
advanced trauma life support courses2 and 
can provide useful information that has the 
potential to alter patient management in 
appropriately selected cases. However, we 
wish to sound a cautionary note for physicians 
performing diagnostic peritoneal lavage.
Our department has previously surveyed a 
representative sample of 40 UK major trauma 
units regarding their ability to analyse  fluid 
samples.3 During normal working hours 
(9 am-5 pm), only 29 of 40 haematology 
departments were able to provide this 
service, falling to nine of 40 outside these 
times. Fourteen departments stipulated that 
the lavage fluid should be collected in EDTA 
bottles, while the remainder had no container 
preference. We also detected variation in the 
returned volume of lavage fluid required for 
analysis, in the infusion fluid required, and in 
the time taken for sample analysis. Only five 
of 40 departments had guidelines in place. 
Given these findings we strongly recommend 
that prior to performing diagnostic peritoneal 
lavage, doctors confirm with their local 
laboratory service both the ability to analyse 
lavage fluid and any special requirements 
for sample handling. This seems particularly 
prudent outside of normal working hours.
Nicholas F S Watson specialist registrar 
John S Hammond consultant surgeon  
Adam Brooks consultant surgeon   
John F Abercrombie consultant surgeon 
Charles A Maxwell-Armstrong consultant surgeon 
Nottingham University hospitals Nhs trust, Nottingham, 
NG7 2Uh nicholas.watson@nottingham.ac.uk
Competing interests: None declared. 
Jansen JO, Yule SR, Loudon MA. Investigation of blunt 1 
abdominal trauma. BMJ 2008;336:938-42. (26 April.)
American College of Surgeons Committee on Trauma. 2 
Advanced trauma life support program for doctors. 
7th ed. Chicago: American College of Surgeons, 2004.
Maxwell-Armstrong C, Brooks A, Field M, Hammond J, 3 
Abercrombie J. Diagnostic peritoneal lavage analysis: 
should trauma guidelines be revised? Emerg Med J 
2002;19:524-5. 
 
plaCeBo effeCt
Reconceptualising placebo
The notion that placebo responses are responses 
that are evoked by nothing is nonsense. The 
study by Kaptchuk et al and the study by 
Waber et al in JAMA illustrate clearly that the 
“placebo”’ responses observed are in fact 
responses to things other than the thing to 
which we hypothesise a response.1 2 Therefore, 
placebo responses reflect the limitations of 
our experimental design, our appreciation of 
the contributors to a patient’s symptoms, and 
our appreciation of what might change those 
underpinning factors. The convincing placebo 
data concern symptoms—experiences reported 
by patients. That means that symptoms are 
outputs of the brain. That a placebo response 
occurs means that something has changed the 
brain’s evaluation of whether or not to evoke 
that symptom. This makes a placebo response 
not a response to nothing, but to something we 
haven’t identified or measured. Take pain for 
example: it emerges according to an implicit 
evaluation of the threat to body tissue and the 
need for action. It is sensible that anything that 
changes this implicit evaluation of threat should 
change pain.
Rather than interpreting “placebo” responses 
as mysterious unexplainable responses to 
nothing, we should, as the editorial hints,3 get 
excited about what else might have led the 
patient’s brain to conclude that the need for 
symptoms had just reduced. To suggest we 
should use the placebo response in clinical 
practice seems a bit daft to me because it is the 
other things (we are yet to identify, accept, or 
understand), which change the brain’s evaluation 
of the need for symptoms, that we should utilise. 
I agree that the alternative therapies are way 
in front of us here—they know they are using 
some of these things, it just doesn’t make them 
conclude that what they do is useless.
G lorimer Moseley Nuffield medical research fellow 
University of oxford, oxford oX1 3QX 
lorimer.moseley@medsci.ox.ac.uk
Competing interests: None declared.
Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, 1 
Jacobson EE, et al. Components of placebo effect: 
randomised controlled trial in patients with irritable 
bowel syndrome. BMJ 2008;336:999-1003. (3 May.)
Waber RL, Shiv B, Carmon Z, Ariely D. Commercial 2 
features of placebo and therapeutic efficacy. JAMA 
2008;299:1016-7.
Spiegel D, Harrington A. What is the placebo worth? 3 BMJ 
2008;336:967-8. (3 May.) 
 
Helping patients feel better
On the basis of their study on the placebo 
response in irritable bowel syndrome, Kaptchuk 
et al conclude that the patient-practitioner 
relationship is the most robust component of 
and Redbridge Trust implemented a programme 
aimed to reduce these infections. This followed 
guidance in the “Saving Lives” programme.1 
Skin decontamination devices (Chlorprep 
Single Swab Applicator) and venflon packs 
were supplied to all wards. Labels for date of 
insertion and removal for peripheral cannulas 
were provided together with Tegaderm to replace 
tape and gauze dressings. Junior doctors and 
nurses were trained to use these packs and, in 
particular, how to label and insert cannulas in an 
aseptic manner.
From June 2007 to March 2008, total episodes 
of MRSA bacteraemia trustwide fell from 56 to 
32 (42.9%) compared with the preceding 10 
months. Over this 20 month period, policies 
on the selective screening of high risk patients 
(critical care, neonates, elective orthopaedic 
surgery, frequent hospital reattenders, and 
patients from care homes) remained unchanged. 
Recently, we screened all patients on six medical 
and surgical wards and showed that MRSA is as 
prevalent in our trust (median prevalence rate 
11.5%, range 7-23%), as St Thomas’s (median 
value 6.1%, range 2.7-19.7%).
Based on Jeyaratnam et al’s finding2 and 
our own experience locally, we believe the 
government target of universal MRSA screening 
of elective inpatients, costing our trust £97 000/
year, is unlikely to affect MRSA bacteraemia 
rates. By March 2011, the government aims to 
screen all hospital inpatients for MRSA, which 
would cost an additional £837 000/year. This 
amount would be five times more expensive 
if polymerase chain reaction assays were 
introduced. In contrast, enhanced bacteraemia 
surveillance and targeted interventions aimed 
at reducing infection at sites that cause MRSA 
bacteraemia is likely to be money well invested. 
Universal screening seems to be wasteful, and 
we believe the government’s strategy to reduce 
MRSA infections through universal screening 
requires a fundamental rethink.
Mark Melzer consultant microbiologist, lindsey Bain 
infection control doctor, Yasmin J Drabu medical director  
Department of microbiology, Queen’s hospital, Barking, 
havering and redbridge trust, romford, Essex rm7 0aG 
mark.melzer@bhrhospitals.nhs.uk
Competing interests: None declared.
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Harrington is spot on: “We treat patients in a 
social and psychophysiological context that 
can either improve or, alas, worsen outcome. 
The meanings and expectations created by 
the interactions of doctors and patients matter 
physically, not just subjectively.”1
It’s time for doctors to reclaim the human 
aspects of their work. Caring for patients with 
due time and attention is not a luxury nor 
superfluous. It has a direct impact on outcomes. 
We cannot reduce medical practice to the 
physical components of our interventions 
because human beings are more than their 
physical components. We are thinking, feeling, 
meaning-seeking creatures. Unless we are 
treated as such we cannot expect the best 
outcomes from our medical experiences.
Robert W leckridge locum consultant, Glasgow 
homeopathic hospital, Glasgow G12 0XQ 
bobleckridge@gmail.com
Competing interests: None declared.
Spiegel D, Harrington A. What is the placebo worth? 1 BMJ 
2008;336:967-8. (3 May.)
Placebolotherapy
I am thinking of setting myself up as a 
placebolotherapist.1 Placebolotherapy—the 
standard by which all other treatments are 
measured. At least as effective as all types of 
psychotherapy and all “alternative” healthcare 
treatments. Treats physical health conditions 
and mental health problems (especially mood 
disorders). Evidence based. No spurious claims 
or pseudoscientific explanations. No reliance 
on ill defined terms such as “energy,” “auras,” 
“crystal power,” or “spirituality.”
Placebolotherapy is not a replacement for any 
proved treatment, it is an enormously helpful 
adjunct.
Placebolotherapists spend an hour with the 
“patient” in a pleasant room, giving them their 
full and undivided attention. They explain that 
what they are doing is backed up by rigorous 
scientific evidence, is extremely effective, and 
that the patient will feel better afterwards.
That’s it. Cost £50 a session. Research into 
placebo shows that the more value the patient 
puts on it, the more effective it is (a placebo 
injection is more effective than a placebo pill), so 
an expensive session will be more effective than 
a cheap one.
Or should I set myself up as a homoeopath?
Nick J Woodhead mental health act coordination manager, 
Bridgwater, somerset ta6 4rN  
nick.woodhead@sompar.nhs.uk
Competing interests: NJW often uses hot lemon cold cures.
Pittrof R, Rubenstein I. The thinking doctor’s guide to 1 
placebos. BMJ 2008;336:1020. (3 May.) 
 
Implementing placebo
Pittrof and Rubinstein make the important point 
that the “placebo effect” is actually an effect—
people often do get better on placebo.1 However, 
most, if not all, of the evidence for placebo effects 
comes from studies where patients expected 
to have a reasonable chance (generally 0.5) of 
receiving the active treatment. There is therefore 
no evidence base for prescribing placebos in 
a standard clinical setting, which is what the 
authors seem to advocate.
We do not know whether placebos will have 
an effect if patients are aware of what they are 
receiving. The most likely explanation for the 
placebo effect, particularly in mental disorders, is 
that it works as a proto-psychotherapy, using the 
patients’ conviction that they are being helped 
and mobilising their own positive resources. We 
know very little about the brain mechanisms of 
the placebo response, but the available evidence 
suggests that, like psychotherapy, it partly 
operates through the same pathways as the 
relevant active drugs.2 I would therefore expect 
the patient’s belief that some aspect of their 
brain chemistry is actually being changed to be a 
crucial part of the placebo effect.
There may still be ways in which patients 
can benefit from placebos, even if they cannot 
be prescribed like ordinary drugs. Firstly, in a 
setting that re-creates the original trial, including 
randomisation to placebo or active treatment, 
but then the physician would not have control 
over who receives the “reduced benefits for 
much reduced risks.”1 Secondly, if physicians 
were to deceive patients, telling them that they 
are receiving an active treatment when they are 
not, this would face both ethical and practical 
challenges. Thirdly, by administering placebo-like 
substances in the context of a quasi-medical 
model such as homoeopathy, but this will work 
only if the patient (and probably the doctor as 
well) believes in this model.
David e linden professor of biological psychiatry 
school of Psychology, Bangor University and North Wales 
Clinical school, Bangor ll572as d.linden@bangor.ac.uk
Competing interests: None declared.
Pittrof R, Rubenstein I. The thinking doctor’s guide to 1 
placebos. BMJ 2008;336:1020. (3 May.)
Linden DE. How psychotherapy changes the brain—the 2 
contribution of functional neuroimaging. Mol Psychiatry 
2006;11:528-38.
the placebo effect.1 Despite some important 
limitations, including extremely brief follow-up 
and potential bias in patient recruitment, their 
findings fit with previous observations that 
the therapeutic relationship is correlated to 
beneficial outcomes.2 However, the inclusion of 
another comparison group would have shed light 
on an important issue they do not discuss—how 
would patients respond to the augmented 
patient-practitioner relationship in the absence 
of sham acupuncture (or any other intervention)?
It is possible that the “doctor as drug” effect 
alone may be stronger than the study indicates.3 
Doctors often feel under pressure to “do 
something,” when much of the time our patients 
may benefit most when we are free to just “be 
someone”—the one who helps them feel better.
T everett Julyan specialist registrar in liaison psychiatry 
stirling royal infirmary, stirling Fk8 2aU 
everett.julyan@nhs.net
Competing interests: None declared.
Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, 1 
Jacobson EE, et al. Components of placebo effect: 
randomised controlled trial in patients with irritable 
bowel syndrome. BMJ 2008;336:999-1003. (3 May.)
Martin DJ, Garske JP, Davis MK. Relation of the therapeutic 2 
alliance with outcome and other variables: A meta-
analytic review. J Consult Clin Psychol 2000;68:438-50.
Balint M. 3 The doctor, his patient and the illness. 2nd ed. 
Oxford: Churchill Livingstone, 2000. 
 
Dangers of placebo
The ins and outs of placebo use in medicine are 
unfortunately forgotten by doctors, especially 
when controlled clinical trials are concerned.1 So 
I would emphasise several dangers of placebo 
use: it spoils the doctor-patient relationship, 
enhances the asymmetric relationship—
paternalism—between physicians who know 
and patients who suffer, can be medically 
dangerous—especially when the doctor’s aim is 
to determine whether patients have an organic 
disease—and strengthens medical arrogance, 
infantilising patients even more.
To quote Howard M Shapiro: “Finally we have 
to consider what may be the greatest danger of all 
for the physician, that giving a placebo will give 
him an even higher opinion of his own abilities 
to help.”2
Jean-Claude Grange general practitioner 78200 mantes-la-
Jolie, France jcgrange@club-internet.fr
Competing interests: None declared.
Spiegel D, Harrington A. What is the placebo worth? 1 BMJ 
2008;336:967-8. (3 May.)
Shapiro HM. 2 Doctors, patients, and placebos. Yale: Yale 
University Press, 1986. 
Human effect is important
The dismissal of non-specific effects of care 
as placebo effects (which are rated as sham, 
pretend, dishonest, or false) does a huge 
disservice to patients and to doctors. The take 
home message in the article by Spiegel and 
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opiuM produCtion in afghanistan
Is the uS or the Taliban 
responsible?
Working for a year in the Kabul children’s 
hospital in the 1970s gave me a perspective 
on Afghanistan that conflicts with the Foreign 
Office’s view that “the Taliban is promoting 
opium production to finance terrorism.”1
The simple facts are that opium production 
was high under the US influenced government 
of Afghanistan of the 1970s, decreased 10-fold 
by 2001 under the Taliban, and then increased 
30-fold and more under the US to the same level 
as in the 1970s.2
History shows us how empires function; 
be they British or US. The East India Company 
organised the opium trade through “free 
traders”—men with fast ships and guns to fend 
off the pirates. One of the most famous free 
traders was Francis Light, founder of the British 
province of Penang. These are facts, whereas the 
idea that the CIA runs opium from Afghanistan 
would be a conspiracy theory—unless, you 
thought about the United Nations statistics or 
happened to have been to Afghanistan.
I wonder if “Clive of the East India Company,” 
whose statue is outside the Foreign Office’s front 
door, has influenced its interpretation of world 
events.
Simon J Spedding medical adviser, Department of Veterans 
affairs, 199 Grenfell street, adelaide, sa 5000, australia 
Simon.spedding@dva.gov.au
Competing interests: None declared.
Malloch-Brown M. Opium production in Afghanistan. 1 
BMJ 2008;336:972. (3 May.)
United Nations Office on Drugs and Crime (Vienna 2 
Office). Afghanistan: opium survey 2004. www.unodc.
org/pdf/afg/afghanistan_opium_survey_2004.pdf 
editorial gives misleading 
impression
Malloch-Brown surely gives a misleading 
impression when he writes that global demand 
for opiates for medical purposes is fully satisfied.1 
The International Narcotics Control Board has 
reported that there is little or no reported medical 
use of any opioid (not just heroin/diamorphine) 
in some two thirds of the world’s countries. 
People there have the same need for the relief of 
pain and suffering, especially in palliative care 
and because of the ravages of AIDS epidemics, 
but they have no access to doctors or other 
prescribers or nobody is willing to prescribe or is 
not allowed to do so. This often results from the 
indiscriminate demonisation/prohibition in anti-
drugs campaigns.
As it happens, we in the United Kingdom are 
now in the fourth year of a major diamorphine 
injection shortage such that street heroin—said 
to be increasingly pure because of abundant 
supply—is much cheaper than diamorphine 
ampoules, the only form licensed for non-oral 
administration. But at least in the UK this is owing 
not to a lack of wholesale diamorphine (we are 
the world‘s largest producer) but to a sudden lack 
of freeze drying capacity at the end of 2004 which 
has never been satisfactorily explained and 
remains unresolved.
Don C Aston retired, solihull B90 2BG  
don.aston@btinternet.com
Competing interests: None declared.
Malloch-Brown M. Opium production in Afghanistan. 1 
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nhs CoMMissioning 
Current system has lost touch 
with reality of patient care
Ham’s dissection of the problems of NHS 
commissioning is welcome to me as it shows I 
am not the lone voice crying in the wilderness 
that I feared I was.1 2
The current system of commissioning has 
lost touch with the reality of patient care. 
Commissioners have become obsessed with 
saving money and have started playing games 
to achieve this. Secondary care services are 
(largely) paid for through the payment by results 
(PbR) tariff, but increasingly we are seeing 
attempts to commission cheaper services by 
finding ways around paying tariff rates. In my 
own area, a consultant service in rheumatology 
has been established in a general practice, so 
not subject to PbR. It costs less than half the PbR 
tariff rate, which I, as an acute trust employee, 
cannot match.
Can my own service go off tariff? Actually it 
seems that it can—by establishing clinics that 
call themselves something else (for example, 
a medical musculoskeletal service). Using 
such a title I can tender my services at a newly 
competitive rate and win back some lost 
business (about 50% of my non-inflammatory 
joint disease caseload). My trust will make less 
of a profit, but it gets some money instead of 
none. It is, of course, unfair for a service to be 
forbidden to set its own price. At least that’s 
what I think, but I can’t get anyone to test this; 
the Competition Commission, the Office of Fair 
Trading, and the trust lawyers refuse to act, and I 
cannot afford to mount a judicial review myself.
In Hillingdon the primary care trust put out 
a tender for the entire musculoskeletal service 
which, I understand, was awarded to a private 
company. The trust set charges that were 
between two thirds and three quarters of the 
PbR tariff. I have been told that the acute trust’s 
lawyers advised that it could not tender below 
tariff and was thus excluded from applying to do 
its own work. The knock-on effects of removing 
an entire service from a hospital are worrying. 
So how has Hillingdon got away with this? Did it 
consult the patients? Would they have agreed? 
From my own experience I doubt it.
If we are to avoid such absurd perversities 
and the need to play games it is essential for 
all barriers to fair competition to be removed. 
However, the risks to existing systems from such 
competition must be factored into any financial 
analysis. 
Andrew N Bamji consultant rheumatologist, Queen mary’s 
hospital, sidcup, kent Da14 6lt bamji@btinternet.com
Competing interests: None declared.
Timmins N. Move to split role of healthcare purchaser and 1 
provider may have to be abandoned, expert says. BMJ 
2008;336:979. (3 May.) 
Ham C. Competition and integration in the English 2 
National Health Service. BMJ 2008;336:805-7. (12 April.) 
nhs dentistrY
General practitioners are  
doing dentists’ work
For some time patients have been finding it 
ever harder to register with an NHS dentist 
and especially to see a dentist outside of core 
working hours. I have noted an increasing 
stream of patients needing to see a doctor for 
what is essentially a dental problem.
I therefore audited the work of our practice, 
which has 10 000 registered patients. I 
analysed all dental related consultations during 
the two years 1996-8 and 2006-8, discovering 
a 1600% rise in their number over this 10 year 
period.
There is no provision in the NHS contract 
for general practitioners to be remunerated 
for dental work, despite health minister Ben 
Bradshaw’s advising patients who could not 
get dental treatment to visit their general 
practitioner.
My audit results may be a symptom of 
declining dental availability. They also show, 
once again, how general practitioners are left to 
pick up work that should be performed by other 
professionals without adequate remuneration.
Alastair Bint general practitioner, st luke’s surgery,  
Guildford GU1 3Jh al@bint69.fsnet.co.uk
Competing interests: None declared.
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